PCK2 as a potential therapeutic target for aggressive MYC-amplified non-WNT/non-SHH medulloblastoma based on tumor continuum.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
Medulloblastoma, the most common malignant pediatric posterior fossa tumor, exhibits metabolic reprogramming and tumor immune microenvironment heterogeneity in non-WNT/non-SHH subgroups, yet the interplay between these features remains poorly defined. Revealing potential molecular features and hidden therapeutic target, we integrated the transcriptomic data of non-WNT/non-SHH medulloblastoma from GEO and EMBL-EBI databases. Through examination of the Grp3/4 transcriptional continuum, we identified PCK2 (a key gene in the TCA cycle with the highest correlation with continuum score). We validated PCK2 as a driver of proliferation, migration, invasion, glycolysis, and M2 macrophage polarization in MYC-amplified MB cells through short hairpin RNA knockdown experiments. Together, our findings establish metabolic-TIME crosstalk as a prognostic determinant and proffer PCK2 as a therapeutic target for aggressive MB subtypes, offering insights into metabolic subtyping and precision therapy strategies to improve clinical outcomes.